enzh-TWfrdeitjaptrues

Phone: 617-632-6964
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Guang Yang has joined as a research fellow with the Bing Center for Waldenstrom’s macroglobulinemia, Dana Farber Cancer Institute this past year. His education began in Beijing, China, earning him a PhD in Biochemistry and molecular biology. Dr Yang has been with the Dana Farber Cancer Institute since 2001, and with a diverse and strong background in biochemistry, molecular biology, immunology and cell biology. He is very proficient in antibody engineering, protein expression and purification, tumor antigen gene screening, RNA splicing and cell morphology research. He is a vital contributor to the Bing Center for Waldenstrom’s macroglobulinemia. Dr Yang is currently working on a variety of projects for the Bing Center for Waldenstrom’s macroglobulinemia. The following is a list of his current publications:


Guang Yang, Shu-Ching Huang, Jane Y. Wu, and Edward J. Benz, Jr. Regulated Fox-2 isoform expression mediates protein 4.1R splicing during erythroid differentiation Blood, 1 January 2008, Vol. 111, No. 1, pp. 392-401.

Yang G, Li Y, Nishimura EK, Xin H, Zhou A, Guo Y, Dong L, Denning MF, Nickoloff BJ, Cui R.. Inhibition of PAX3 by TGF-beta modulates melanocyte viability, Mol Cell, 2008, 32(4): 554-63.

Guang Yang, Shu-Ching Huang, Jane Y. Wu, and Edward J. Benz, Jr. An erythroid differentiation–specific splicing switch in protein 4.1R mediated by the interaction of SF2/ASF with an exonic splicing enhancer Blood, 1 March 2005, Vol. 105, No. 5, pp. 2146-2153

Yang G, Ran YL, Sun LX, etc. High Expression in CHO Cells and Activity of an Anti-P185(erbB2) Mouse/human Chimeric Antibody. Acta Biochemica et Biophysica Sinica, 2001, 33 (1): 87-92

Yang G, Ran YL, Sun LX, etc. Activity identification of an anti-P185erbB2 McAb C25 ad cloning of its variable region genes. Chinese Journal of Cancer, 200, 19(8): 735-738

Yang G, Yang ZH, Sun LX, etc. Preparation and identification of monoclonal antibodies against P185erbB2. Immunological Journal, 2000, 16 (2): 139-141

Yang G, Zhao JY, Xu GY, Yang PM. The quantitative study on the alteration of leukemia MDR cell line CEM/ADM in ultra structure. Progress of Anatomical Sciences, 1996, 2 (3): 260-262.

Shao SJ, Xu GY, Ling MY, Yang G. A comparison study on the ultra structure of sub-clonal cell lines with different metastatic ability. Progress of Anatomical Sciences, 1997, 3 (3): 204-207.

Latest Bing Center News

Making Sense of the Science of WM with Dr. Zachary Hunter

Making Sense of the Science of WM with Dr. Zachary Hunter

Making Sense of the Science of WM sets out a framework for patients to understand the basic genetic concepts behind the mutations that are important in WM, to appreciate the ways in which these mutations impact the signaling systems that control the behavior of WM cells, and to recognize how these mutations are changing the landscape of therapies for WM.

Read more..

Steven P. Treon, MD, PhD, on Treating COVID-19–Related Pulmonary Failure by Targeting BTK With Ibrutinib

Steven P. Treon, MD, PhD, on Treating COVID-19–Related Pulmonary Failure by Targeting BTK With Ibrutinib

Steven P. Treon, MD, PhD, of Dana-Farber Cancer Institute, discusses Bruton’s tyrosine kinase (BTK), which is activated during severe COVID-19 infection. Patients with the coronavirus and chronic lymphocytic leukemia who remained on the BTK inhibitor ibrutinib had a mild disease course, with decreased C-reactive protein and improved oxygenation. Clinical trials to validate the role of BTK inhibitors in treating COVID-19–related pulmonary distress are now underway.

Read more..

Next Generation BTK-Inhibitors in Waldenstrom's Macroglobulinemia

Next Generation BTK-Inhibitors in Waldenstrom's Macroglobulinemia

Dr. Steven Treon delivered this on-line lecture on August 5, 2020 for the benefit of the WMFC Toronto Support Group. It is our privilige to share it with the entire WM community.  It focuses on the role of BTK Inhibitors in the treatment of Waldenstrom's Macroglobulinemia, and the advances being made based on the latest research.

Read more..

2020 IWMF GLOBAL EDUCATIONAL WEBINAR: Getting to Know WM: Basics & Beyond with Dr. Jeffrey Matous

2020 IWMF GLOBAL EDUCATIONAL WEBINAR: Getting to Know WM: Basics & Beyond with Dr. Jeffrey Matous

The International Waldenstrom's Macroglobulinemia Foundation invites you to join us for the first installment in our 2020 IWMF Global Educational Webinar series.

Read more..

Waldenstrom Patient Stories: Finding Strength

Waldenstrom Patient Stories: Finding Strength

When Peter DeNardis was diagnosed with Waldenstrom macroglobulinema (WM) 17 years ago, all he knew was that he had an incurable cancer. He had never heard of this rare type of non-Hodgkin lymphoma. A married father of three in his early 40s, DeNardis worried about how his illness would impact his family. How would his passing affect them emotionally and financially?

Read more..

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic

In the light of the COVID-19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel felt the need to provide a consensus statement for the management of Waldenström Macroglobulinemia (WM) patients during this challenging time.

Read more..

IWMF Virtual Educational Forum - August 27-28, 2020

IWMF Virtual Educational Forum - August 27-28, 2020

As most of you know, the 2020 IWMF Educational Forum will be virtual/online and is coming soon (August 27-28) - see agenda and registration details at: https://www.iwmf.com/news-and-events/iwmf-educational-forum.

Read more..

The WMFC hosts virtual session with Dr. Zachary Hunter

The WMFC hosts virtual session with Dr. Zachary Hunter

The WMFC (the Canadian affiliate of the IWMF) was proud to have Dr. Zachary Hunter of the Dana-Farber Cancer Institute join the Atlantic Canada WM Support Group for a recent virtual meeting. Dr Hunter described the latest research into Waldenstrom’s macroglobulinemia. After his talk, he took questions from the participants and described the latest research project he is taking on with the financial backing of the WMFC, IWMF, LLS and the Leukemia Foundation of Australia.

Read more..

New Waldenstrom Macroglobulinemia Patient Story of Hope

New Waldenstrom Macroglobulinemia Patient Story of Hope

Peter DeNardis was diagnosed with Waldenstrom macroglobulinemia in 2003 and is a board member for the International Waldenstrom’s Macroglobulinemia Foundation (IWMF). He shares his personal story of living with Waldenstrom and explains how new treatments for Waldenstrom macroglobulinemia are evolving. He also shares why patients who have this rare cancer can finally be hopeful about the future.

Read more..

Dana-Farber/Brigham and Women’s Cancer Center is ranked the best in New England

Dana-Farber/Brigham and Women’s Cancer Center is ranked the best in New England

Dana Farber/Brigham and Women’s Cancer Center has been recognized as a Best Hospital for 2020-21 by U.S. News & World Report.  For the 20th straight year, Dana-Farber/Brigham and Women’s Cancer Center is ranked as the best hospital for cancer care in New England and is ranked #6 in the nation this year.

Read more..